COAG Stock — Hemab Therapeutics Holdings Inc.: Cash, EV, Pipeline

Share price

$41.19

Market cap

$1,924.1M

Cash

$457.5M

Enterprise value

$1,466.6M

Balance sheet

Cash	$457.5M
Debt	$0.0M
Net cash	$457.5M
Enterprise value	$1,466.6M
Basic shares	30.1M shares
Fully diluted shares	55.2M shares
Fully diluted market cap	$2,275.1M
Cash per share	$15.20

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading COAG daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Jun 11 - Jul 23	HMB-003	Phase 1	Healthy Adult Participants	—
Aug 12 - Sep 23	HMB-002 (Part A)	Phase 1/2	Von Willebrand Disease (VWD); Von Willebrand Disease (VWD), Type 1; Von Willebrand Disease (VWD), Type 2	—
Sep 12 - Oct 24	HMB-001	Phase 1/2	Glanzmann Thrombasthenia	—
Dec 13, 2027 - Jan 24, 2028	Sutacimig	Phase 2	Congenital Factor VII Deficiency	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

sutacimig

Phase 1 · Active Modality: bispecific antibody

Aliases HMB-001

Target TLT-1 / Factor VII

Partnerships Novo Nordisk: license to TLT-1/FVII bispecific antibody IP; Genmab: DuoBody platform license

Indications

Glanzmann thrombasthenia (prophylaxis) (Phase 1)
Factor VII deficiency (prophylaxis) (Phase 2)

Status note Lead asset. Phase 1/2 in Glanzmann thrombasthenia; Phase 2 in Factor VII deficiency. July 2026: sustained prophylactic effect in long-term extension of Phase 2 GT trial; identified 0.2 mg/kg once-weekly dose for planned Phase 3, endorsed by FDA.

HMB-002

Phase 1 · Active Modality: monovalent antibody

Indications

Von Willebrand Disease (subcutaneous prophylaxis) (Phase 1)

Status note Second clinical-stage asset; Phase 1/2 in subcutaneous prophylactic treatment of Von Willebrand Disease.

HMB-003

Preclinical · Active

Target plasmin

Indications

coagulation disorders (Preclinical)

Status note Preclinical program in coagulation disorders; no further detail in filing excerpts.

Per-asset detail extracted from the 10-Q filed 2026-08-11. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Sutacimig
Lead indication	Congenital Factor VII Deficiency
Lead phase	Phase 2
Active trials	5
Collaborator trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07347249	Phase 2	Recruiting	Sponsor	Hemab ApS	—	Congenital Factor VII Deficiency	—
NCT06754852	Phase 1/2	Recruiting	Sponsor	Hemab ApS	—	Von Willebrand Disease (VWD); Von Willebrand Disease (VWD), Type 1; Von Willebrand Disease (VWD), Type 2	—
NCT06211634	Phase 1/2	Active, not recruiting	Sponsor	Hemab ApS	—	Glanzmann Thrombasthenia	—
NCT07798505	Phase 1	Recruiting	Sponsor	Hemab ApS	—	Healthy Adult Participants	—
NCT06610201	Not disclosed	Recruiting	Sponsor	Hemab ApS	—	Von Willebrand Disease (VWD); Von Willebrand Disease (VWD), Type 1; Von Willebrand Disease (VWD), Type 2	—
NCT04398628	Not disclosed	Recruiting	Collaborator	American Thrombosis and Hemostasis Network	NVO, PFE, SNY	Hematologic Disorder; Bleeding Disorder; Connective Tissue Disorder	—

Sponsor-matched active trials from ClinicalTrials.gov (5 as sponsor, 1 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 6 active trials for Hemab ApS on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
Braidwell LP	160,000	+160,000	0.22%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

COAG — Hemab Therapeutics Holdings Inc.

Balance sheet

Price history

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Institutional holders